About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
PROSCA & BLADDR 2022
PROSCA
BLADDR
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
V
Multiple Cases Discussion: Oligometastatic Bladder Cancer
By
PROSCA & BLADDR 2022
FEATURING
Valérie Fonteyne
,
Kilian Gust
,
Ursula Vogl
,
Petros Grivas
By
PROSCA & BLADDR 2022
FEATURING
Valérie Fonteyne
,
Kilian Gust
,
Ursula Vogl
,
Petros Grivas
0 views
December 28, 2022
Comments
0
Login to view comments.
Click here to Login
BLADDR
23:04
PROSCA & BLADDR 2022
Neoadjuvant Systemic Therapy for MIBC
Feat.
T. Powles
14:45
PROSCA & BLADDR 2022
Update on Perioperative Systemic Therapies for UTUC
Feat.
K. Gust
15:26
PROSCA & BLADDR 2022
New Roadmaps for Bladder Preservation in High-Risk NMIBC in 2022
Feat.
J. Irani
13:03
PROSCA & BLADDR 2022
The Role of Systemic Therapy for Bladder Preservation Strategies in …
Feat.
A. Bamias
06:54
PROSCA & BLADDR 2022
Intravesical IO in High Risk NMIBC: A HGUCG Study
Feat.
C. Fragkoulis
28:06
PROSCA & BLADDR 2022
Multidisciplinary Management of Pts With MIBC: Real World Patient Ca…
Feat.
M. De Santis,
A. Choudhury,
A. Drakaki,
T. Klatte
10:09
PROSCA & BLADDR 2022
Transurethral Resection of Bladder Tumor
Feat.
M. Moschini
13:52
PROSCA & BLADDR 2022
Genomic and Tumor Characterisation of UTUC
Feat.
E. Comperat
11:57
PROSCA & BLADDR 2022
Clinical Utility of ctDNA Analysis in Bladder Cancer
Feat.
B. Szabados
12:57
PROSCA & BLADDR 2022
The Role of Palliative and Best Supportive Care in Bladder Cancer
Feat.
D. De Maeseneer
16:45
PROSCA & BLADDR 2022
Lessons From Failed Clinical Trials for Bladder Cancer
Feat.
R. Jones
38:03
PROSCA & BLADDR 2022
Multiple Cases Discussion: Oligometastatic Bladder Cancer
Feat.
V. Fonteyne,
K. Gust,
U. Vogl,
P. Grivas
15:42
PROSCA & BLADDR 2022
Transurethral Resection of Bladder Tumor: Challenges and Opportuniti…
Feat.
M. Moschini
14:03
PROSCA & BLADDR 2022
Considerations for Radical Cystectomy
Feat.
B. Konety
17:44
PROSCA & BLADDR 2022
RT of the Bladder: Clinical Practice and Recent Advancements
Feat.
A. Choudhury
12:39
PROSCA & BLADDR 2022
The Emerging Role of Maintenance Therapy in Bladder Cancer
Feat.
R. Jones
16:02
PROSCA & BLADDR 2022
The Growing Landscape of Antibody-Drug Conjugates in Advanced UC
Feat.
P. Grivas
13:35
PROSCA & BLADDR 2022
Clarifying the Position of Immunotherapies for mUC
Feat.
B. Szabados
06:37
PROSCA & BLADDR 2022
DEBATE: Are We Evolving Towards a Platinum-Free Future in Bladder Ca…
Feat.
M. De Santis
07:13
PROSCA & BLADDR 2022
DEBATE: Are We Evolving Towards a Platinum-Free Future in Bladder Ca…
Feat.
A. Bamias
07:19
PROSCA & BLADDR 2022
Final Results of the HIVEC-HR Randomised Trial Comparing Hyperthermi…
Feat.
F. Guerrero-Ramos
05:26
PROSCA & BLADDR 2022
Concurrent CRT for MIBC Using 5-Fluorouracil vs. Capecitabine: A Nat…
Feat.
L. van Hoogstraten
10:43
PROSCA & BLADDR 2022
Assessment of Molecular Biomarkers for Bladder Cancer Diagnosis, Pro…
Feat.
H. El Ahanidi
23:34
PROSCA & BLADDR 2022
Bladder Cancer Case Discussion: Staging and Follow-Up of Pts With No…
Feat.
T. Klatte,
D. Mitropoulos,
J. Irani,
R. Meijer,
M. Moschini,
N. James
08:46
PROSCA & BLADDR 2022
Bladder Cancer: Is It Time to Revise the Pathway?
Feat.
N. James
09:34
PROSCA & BLADDR 2022
Radical Cystectomy With Ileal Conduit: Lessons to Be Learned
Feat.
R. Meijer
10:19
PROSCA & BLADDR 2022
Uro-Stoma Care: Where Are We Now
Feat.
B. Thoft Jensen
15:01
PROSCA & BLADDR 2022
Urinary Biomarkers in Bladder Cancer Surveillance: Where Do We Stand?
Feat.
T. Klatte
